I must have had this conversation hundreds of times with doctor friends of mine. Namely, I keep bringing up the issue that curing a disease is really not a good business model for most pharma companies. The response I always get is that this is a conspiracy theory with no evidence behind it, and that there is a ton of money to be made in curing something like diabetes, CVD or Alzheimer. So, as I keep getting told, all biotech companies actively try to produce something that actually cures a disease.
Well, one company took that approach and is now brutally punished by Wall Street. Goldman Sachs's analysts actually took the rare step of stating that curing a chronic disease indeed NOT a good business model and the stock has since tanked. So, don't expect a true cure to come any time soon from a publicly traded company that is mandated by law to increase shareholder value and not do much else.
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
"...Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution". "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
"...Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines …"
Well, one company took that approach and is now brutally punished by Wall Street. Goldman Sachs's analysts actually took the rare step of stating that curing a chronic disease indeed NOT a good business model and the stock has since tanked. So, don't expect a true cure to come any time soon from a publicly traded company that is mandated by law to increase shareholder value and not do much else.
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
"...Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution". "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
"...Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines …"